Collegium Pharmaceutical, Inc.
COLL
$38.58
-$0.19-0.49%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 707.01M | 664.28M | 631.45M | 599.25M | 576.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 707.01M | 664.28M | 631.45M | 599.25M | 576.65M |
| Cost of Revenue | 88.30M | 86.07M | 83.53M | 79.91M | 79.39M |
| Gross Profit | 618.71M | 578.22M | 547.92M | 519.33M | 497.26M |
| SG&A Expenses | 249.84M | 217.42M | 182.98M | 157.28M | 150.51M |
| Depreciation & Amortization | 207.22M | 186.26M | 165.30M | 144.35M | 139.86M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 545.36M | 489.75M | 431.82M | 381.54M | 369.76M |
| Operating Income | 161.65M | 174.53M | 199.63M | 217.71M | 206.90M |
| Income Before Tax | 53.00M | 65.07M | 98.57M | 128.01M | 141.21M |
| Income Tax Expenses | 16.73M | 21.17M | 29.38M | 39.42M | 41.32M |
| Earnings from Continuing Operations | 36.27 | 43.89 | 69.19 | 88.59 | 99.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.27M | 43.89M | 69.19M | 88.59M | 99.89M |
| EBIT | 161.65M | 174.53M | 199.63M | 217.71M | 206.90M |
| EBITDA | 373.08M | 364.82M | 368.79M | 365.82M | 350.41M |
| EPS Basic | 1.13 | 1.36 | 2.14 | 2.74 | 3.06 |
| Normalized Basic EPS | 1.73 | 2.11 | 2.70 | 3.16 | 2.91 |
| EPS Diluted | 1.03 | 1.21 | 1.85 | 2.42 | 2.68 |
| Normalized Diluted EPS | 1.41 | 1.71 | 2.15 | 2.51 | 2.30 |
| Average Basic Shares Outstanding | 127.94M | 128.56M | 129.10M | 129.32M | 130.81M |
| Average Diluted Shares Outstanding | 152.19M | 153.50M | 162.10M | 163.27M | 165.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |